786ANDROGEN RECEPTOR IN TRIPLE NEGATIVE BREAST CANCERThough many recent developments have been provided in terms of breast cancer treatments and targeted therapy, the incidence of breast cancer is increasing throughout the world and it is the leading cause of cancer death in females. The most heterogeneous type of breast cancer is the triple negative breast cancer (TNBC), involving many subtypes and mixed entities which differ in many aspects: histology, molecular markers, prognosis, treatment and patient outcomes. Triple negative breast cancer is also the most aggressive type of breast cancer due to its lack of hormone receptors and HER2 amplification. Recent studies have demonstrated the implication of androgen receptor (AR) in prognosis and therapy of TNBC although this has not yet been completely elucidated. The aim of this review is to provide an overview about TNBC and to state androgen receptor role and its importance in therapy of breast cancer in the near future.Petra_elhajj@hotmail.comReview832017Triple Negative Breast Cancer,Androgen Receptor,Luminal Androgen Receptor,Anti-Androgen,Prognosis,Therapy,Disease free survivalPetra EL Hajj,Razan Jarjour,Fadi Nasr,Khaled Habib, Evelyne EL Helou,Mona Diab-AssafMolecular Tumorigenesis and Anticancer Pharmacology, EDST, Lebanese University, Hadat, Lebanon.,Molecular Tumorigenesis and Anticancer Pharmacology, EDST, Lebanese University, Hadat, Lebanon.,Faculty of Medicine, Lebanese University, Hadat, Lebanon.,Specialized Medical Laboratory, Al-Mazraa, Beirut, Lebanon.,Hematology-Oncology Department, Lebanese Hospital University Medical Center, Beirut, Lebanon.,Molecular Tumorigenesis and Anticancer Pharmacology, EDST, Lebanese University, Hadat, Lebanon.